Brief Limb Ischaemia Cycles Shield the Kidneys by Switching On a Mitochondrial Cleanup Pathway

When blood flow to the kidneys is cut off and then restored, as happens during procedures such as percutaneous coronary intervention, the returning oxygen itself becomes a weapon. Mitochondria in the energy-hungry cells lining the kidney tubules are damaged by the ischaemic insult, spew out reactive oxygen species, and trigger inflammatory cascades and cell death. The result can be acute kidney injury, a serious complication of cardiac catheterisation that carries substantial morbidity and mortality. A new study published in the Journal of Cellular and Molecular Medicine offers a detailed mechanistic explanation for how a remarkably simple, non-invasive manoeuvre—briefly squeezing a limb to cut off and restore its blood supply—can protect the kidneys from this damage. The answer, the researchers report, lies in a molecular quality-control programme centred on the mitochondrial deacetylase SIRT3 and the ubiquitin ligase Parkin.

The intervention in question is remote ischaemic preconditioning, or RIPC. In the experimental setting used by the team at Baotou Medical College, a blood-pressure cuff on a mouse’s right hind limb was inflated and deflated in four cycles of five minutes of ischaemia and five minutes of reperfusion, two hours before the kidneys were subjected to injury. The idea is counterintuitive: deliberately starving a distant limb of oxygen primes the body’s defences so that a later, more dangerous ischaemic episode elsewhere does far less harm. RIPC has previously been shown to protect the heart, liver and brain, and to induce autophagy in those organs, but the specific molecular route by which it guards the kidney had remained unresolved.

To test the protective effect, the researchers clamped both renal pedicles of male C57BL/6 mice for thirty minutes and then allowed twenty-four hours of reperfusion. Untreated injured mice fared badly: blood urea nitrogen climbed to 26.47 mmol/L and serum creatinine to 151.90 μmol/L, while histology revealed widespread swelling and necrosis of the renal tubules. Mice that had received limb RIPC beforehand showed significantly better kidney function, with BUN and creatinine falling to 14.69 mmol/L and 100.90 μmol/L respectively, milder tubular damage on blinded pathological scoring, and far fewer dying cells. TUNEL staining revealed that RIPC cut the number of apoptotic tubular cells from roughly 27 to about 11 per square millimetre of tissue, and the apoptosis-execution protein cleaved-caspase-3, sharply elevated by injury, was substantially reduced by the preconditioning.

The next question was how RIPC achieves this rescue. Because mitochondria are both the primary energy source for tubular cells and the most vulnerable casualty of ischaemia–reperfusion, the team focused on mitophagy—the selective autophagic disposal of damaged mitochondria. Using the JC-1 fluorescent probe, they showed that injury collapsed the mitochondrial membrane potential in tubular cells, a hallmark of organelle dysfunction, whereas RIPC pretreatment preserved it. Critically, when the researchers blocked early autophagy with 3-methyladenine before RIPC, the protection vanished: membrane potential fell, BUN and creatinine rebounded to near-injury levels, and cleaved-caspase-3 rose again. Mitophagy, in other words, is not an incidental by-product of RIPC but a necessary downstream effector of its renoprotective action.

Molecular and ultrastructural evidence reinforced the point. Western blotting of mitochondrial fractions showed that RIPC increased the LC3-II/LC3-I ratio and decreased p62, the canonical biochemical signature of active autophagic flux, while electron microscopy of tubular cells revealed a marked increase in double-membrane autophagosomes and single-membrane autolysosomes containing degraded mitochondrial material. Inhibiting autophagy with 3-methyladenine reversed all of these changes. The team also verified that the flux was complete rather than blocked: chloroquine, which prevents the fusion of autophagosomes with lysosomes, caused further accumulation of LC3-II and p62 in RIPC-treated cells, exactly what would be expected if RIPC were driving a genuine, functional degradative pathway rather than merely stalling traffic.

To dissect the molecular trigger, the investigators turned to SIRT3, an NAD+-dependent deacetylase that resides in mitochondria and governs biogenesis, oxidative stress resistance and energy metabolism. The kidney, one of the most energy-demanding organs in the body, is rich in SIRT3, and prior work had shown that deleting the gene worsens ischaemic tubular damage while overexpressing the protein protects it. In cultured human HK-2 tubular cells subjected to hypoxia and reoxygenation, plasma taken from rats that had undergone limb RIPC—the standard laboratory mimic of the humoral protective signals released by the manoeuvre—preserved cell morphology, reduced apoptotic rates measured by flow cytometry, maintained membrane potential, and upregulated the mitophagy genes LC3 and Beclin1 at both mRNA and protein levels.

The causal role of SIRT3 was then tested from both directions. When the researchers silenced SIRT3 with siRNA in HK-2 cells, the benefits of RIPC plasma largely evaporated: cells swelled and died, mitochondrial LC3-II and Beclin1 fell, and apoptosis climbed. Conversely, overexpressing SIRT3 reproduced the protective, mitophagy-promoting effect. In vivo, the team generated SIRT3 knockout mice using CRISPR/Cas9 gene editing and confirmed complete loss of the transcript in renal mitochondria. When these knockout animals received the same limb RIPC protocol before renal ischaemia–reperfusion, the protection seen in wild-type mice was abolished: BUN rose to 28.19 mmol/L and creatinine to 161.60 μmol/L, cleaved-caspase-3 increased, the LC3-II/LC3-I ratio dropped and p62 accumulated. SIRT3, the data show, is indispensable for RIPC-induced mitophagy and renoprotection.

The final piece of the mechanism concerns the executive machinery that physically tags damaged mitochondria for destruction. Parkin, an E3 ubiquitin ligase, decorates impaired mitochondria with ubiquitin chains, and the subsequent colocalisation of Parkin with the autophagosomal marker LC3B is the defining event in mitophagosome formation. Immunofluorescence imaging of mouse kidney tissue revealed that ischaemia–reperfusion injury markedly reduced Parkin–LC3B colocalisation in tubular mitochondria, while RIPC pretreatment restored it; blocking autophagy with 3-methyladenine eliminated this restoration. Together with the genetic and pharmacological data, this positions the Parkin-mediated pathway as the downstream executor of SIRT3-dependent mitophagy in RIPC-induced renal protection. The authors also confirmed that RIPC plasma alone, without hypoxic injury, was neither toxic nor disruptive of basal mitophagy, underscoring the specificity of the effect.

The study is not without limitations, which the authors acknowledge candidly. 3-Methyladenine is a non-specific PI3K inhibitor with effects beyond autophagy; the precise molecular mechanism by which SIRT3 regulates Parkin-mediated mitophagy remains to be defined; the in vitro experiments used rat rather than human RIPC plasma; and the model reproduces renal ischaemia–reperfusion rather than contrast-induced kidney injury directly. The absence of SIRT3 knockout sham and injury groups, constrained by animal availability and the 3R principle, also limits formal genotype–treatment interaction analysis. Even so, the causal chain assembled here—RIPC, SIRT3 upregulation, intact mitophagic flux, Parkin-mediated mitophagosome formation, reduced apoptosis, preserved renal function—is unusually complete for a preclinical study of this kind.

The translational implications are considerable. Limb RIPC is cheap, non-invasive and already feasible in patients undergoing percutaneous coronary intervention, and earlier clinical work has suggested that ischaemic preconditioning can reduce contrast-induced nephropathy. By identifying SIRT3 and the Parkin pathway as the molecular core of RIPC’s renal benefit, the study opens the door to pharmacological strategies that could amplify or substitute for the mechanical intervention, potentially combining cuff-based preconditioning with mitophagy-enhancing drugs. Future work with human RIPC plasma, more selective mitophagy modulators and direct models of contrast-induced acute kidney injury will be needed to convert this mechanistic insight into bedside practice, but the prospect of protecting the kidneys with a blood-pressure cuff and a well-chosen molecular target is a striking example of how understanding a pathway can turn a clinical curiosity into a rational therapy.

Subject of Research: SIRT3/Parkin-mediated mitophagy as the mechanism of remote ischaemic preconditioning protection against renal ischaemia–reperfusion injury

Article Title: RIPC Protects Against Renal Ischaemia–Reperfusion Injury by Activating SIRT3/Parkin‐Mediated Mitophagy

Article References: Cui, Q., Zhao, L., Dai, W., Sun, S., Li, Y., Zhou, C., & Pei, H. (2026). RIPC Protects Against Renal Ischaemia–Reperfusion Injury by Activating SIRT 3/Parkin‐Mediated Mitophagy. Journal of Cellular and Molecular Medicine, 30(19), Article e71372. https://doi.org/10.1111/jcmm.71372

Image Credits: AI Generated

DOI: 10.1111/jcmm.71372

Keywords: remote ischaemic preconditioning, acute kidney injury, renal ischaemia-reperfusion injury, mitophagy, SIRT3, Parkin, mitochondria, autophagy, apoptosis, percutaneous coronary intervention, HK-2 cells, CRISPR knockout